84 results about "Antiplatelet drug" patented technology

A method for obtaining a percent aggregation or inhibition of platelets resulting from anti-platelet using a single blood sample is achieved. An assay device is provided. The assay device has multiple channels, each coupled to a common introduction port. A first platelet activator is sensitive to activation pathway targeted by the anti-platelet drug. A second platelet activator is insensitive to the activation pathway targeted by the anti-platelet drug. An anti-coagulated sample is introduced simultaneously to the first and second channels. A level of platelet aggregation is simultaneously made in both channels.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

The invention relates to a prasugrel pamoate salt and a preparation method thereof. The prasugrel pamoate salt has a structure represented by the formula II, and has the advantages of good stability, low hygroscopicity, and high safety. Moreover, the preparation method has the advantages of simple operation and good repeatability. The provided prasugrel salt can be used as an anti-platelet drug.

A slide fastener bioabsorbable stent is applied as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent includes a snap fastener stent, an edge slide fastener stent, a middle slide fastener stent, and a double fastener stent. The slide fastener bioabsorbable stent has good degradability and biocompatibility, and is more suitably used as a pediatric vascular stent, with which no late-onset stent thromboses after implanted, and thus it is not necessary to long-term take antiplatelet drugs and the subsequent surgical operation may not be affected. Also, it has a strong support, and thus can be widely used as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent has simple production and convenient drug carrying, which can be used as a carrier of medicine or gene treatment. The stent can be matched with a delivery system, hence the difficulty of the surgery operation is reduced. Many animal experiments show that slide fastener bioabsorbable stent has high success ratio when being used, and has apparent curative effect and good clinical application prospect.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Described herein are methods of preserving a tissue of a subject, such as a brain or a portion thereof. The methods include washing the tissue by perfusing the tissue with a wash fluid comprising an aqueous solution; fixing the tissue by perfusing the tissue with a fixation fluid comprising an aldehyde; and cryoprotecting the tissue by perfusing the tissue with a cryoprotection fluid comprising avitrification agent. The wash fluid, the fixation fluid, and / or the cryoprotection fluid can include a dye or a contrast agent to monitor perfusion of the fluid through the tissue. In certain embodiments, the cryoprotection fluid has a vitrification temperature of about -80 DEG C or higher. The wash fluid can further include one or more of an ion channel blocker, a calcium chelator, a thrombolyticagent, an anti-platelet, a respiratory poison, or a synaptic poison. Also described herein are methods of analyzing the preserved tissue.

The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I:wherein,X is N, or CR1d,Xb1-Xb5 are the same or different, and are nitrogen or carbon,R1a-R1d are the same or different, and are hydrogen, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted alkylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino,R2 is an optionally substituted aryl or an optionally substituted heteroaryl,R3 is an optionally substituted aryl or an optionally substituted heteroaryl, orpharmaceutically acceptable salt thereof as an active ingredient.

The invention relates to a kit for detecting an antiplatelet drug in blood plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The pretreatment processis simple, the cost is low, the sensitivity is high, the specificity is high, separation and detection of the antiplatelet drug are completed within 5 min, the accuracy and precision basically meet the requirements, the method can be used for quantitative analysis of the clinical antiplatelet drug, and a reliable detection method is provided for monitoring the treatment concentration of the clinical antiplatelet drug.

The invention relates to the technical field of medical examination, and specially relates to a method for simultaneous determining concentrations of ticagrelor and active metabolites and endogenous adenosine thereof in human plasma by liquid chromatography-mass spectrometry. The concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma are simultaneously determined by adopting a liquid chromatography-mass spectrometry technology. The method comprises the following steps: A, simultaneously determining the concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma; B, all the samples to be detected can be subjected to peak determination under the same chromatographic and mass spectrometric conditions;and C, simultaneously extracting to-be-detected substances with different polarities in the sample. The method has the advantages that the adenosine concentration change in the blood plasma in the body of the patient and the relationship between the adenosine concentration change and the concentration of the ticagrelor and the active metabolite thereof in the blood plasma after the antiplatelet drug ticagrelor is taken can be accurately, simply, conveniently and quickly evaluated. In addition, pretreatment and chromatographic and mass spectrometric conditions are optimized, so that the determination method is simple, quick and sensitive to operate, high in specificity and good in repeatability.